Cited by 122Cannabis and Cannabinoid ResearchAutism Spectrum Disorder ResearchNeuroendocrine regulation and behavior

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index; none of the 44 sources its claims cite is checked for support yet.

Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment

Open access
Wei, Don, Dinh, Drake, Lee, DaYeon, Li, Dandan, Anguren, Allison, Moreno-Sanz, Guillermo, Gall, Christine M., Piomelli, Daniele·2016·Cannabis and Cannabinoid Research

Abstract

Introduction: We recently uncovered a signaling mechanism by which the endocannabinoid anandamide mediates the action of oxytocin, a neuropeptide that is crucial for social behavior, to control social reward. Oxytocin signaling has been implicated in autism spectrum disorder (ASD), and social reward is a key aspect of social functioning that is thought to be disrupted in ASD. Therefore, as a proof of principle for the core component of ASD—social impairment—we tested an endocannabinoid-enhancing compound on two widely studied mouse models of ASD, the BTBR and fmr1−/− (model of Fragile X Syndrome). Methods: We used the established three-chambered social approach test. We specifically increased the activity of anandamide by administering the compound URB597, a selective inhibitor of fatty acid amide hydrolase (FAAH), the hydrolytic enzyme for anandamide. Results: Remarkably, we found that FAAH blockade completely reversed the social impairment in both mouse models. CB1 receptor blockade prevented the prosocial action of FAAH inhibition in BTBR mice. These results were likely independent of effects on anxiety, as FAAH inhibition did not alter the performance of BTBR mice in the elevated plus maze. Conclusions: The results suggest that increasing anandamide activity at CB1 receptors improves ASD-related social impairment and identify FAAH as a novel therapeutic target for ASD.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

In two mouse models of autism-related social impairment, pharmacological inhibition of FAAH with URB597 increased anandamide signaling and corrected social approach deficits; the effect in BTBR mice was blocked by CB1 antagonism and was not explained by reduced anxiety. These findings identify FAAH as a candidate therapeutic target for ASD-related social impairment.

Key findings

  • URB597 (0.3 or 1 mg/kg i.p., 3 h before testing) significantly increased social chamber time and sniffing in BTBR mice to levels comparable to C57Bl6J controls; concomitant AM251 (2 mg/kg i.p.) prevented this prosocial effect (n=12–16).
  • In fmr1−/− mice, URB597 (0.3 mg/kg i.p.) increased social chamber time and sniffing to control levels, while no effect was seen in wild-type fmr1+/+ (FVB/NJ) mice; the baseline fmr1−/− social deficit was not statistically significant in this study (n=12–14 per group).
  • URB597 inhibited FAAH and substantially increased forebrain anandamide in BTBR mice without affecting 2-AG. In the elevated plus maze, URB597 (1 mg/kg i.p.) did not alter open-arm time or entries in BTBR mice (n=10 per group), suggesting the prosocial effect was not due to general anxiolysis.
  • In socially normal C57Bl6J mice, neither AM251 (2 mg/kg i.p.) nor URB597 (1 mg/kg i.p.) altered social chamber time or sniffing.

Methods

  • Preclinical proof-of-principle study using male mice (8–10 weeks) bred at UC Irvine, group-housed and naive for each behavioral experiment. Models included BTBR, fmr1−/− (FVB/NJ), C57Bl6J, and wild-type fmr1+/+.
  • Behavioral testing used the three-chamber social approach test (10-min test; choice between novel object and a sex-, age-, and weight-matched 129/SvImJ mouse; 5 lux lighting; automated chamber-time scoring and blinded sniffing scoring) and the elevated plus maze. Biochemical assays included a FAAH enzymatic activity assay and LC/MS lipid quantification.
  • URB597 and AM251 were administered i.p. 3 h before testing. Statistical analysis used two-tailed Student’s t-test and one-way or two-way ANOVA with Tukey’s post hoc test; significance was p<0.05 (GraphPad Prism).

Limitations

  • Stated in the paper: interpretation of BTBR data is limited by possible polygenetic contributions to this inbred strain’s phenotype; fmr1−/− mice were not tested in the elevated plus maze because they display an innate open-arm preference that could confound interpretation; the social approach test may have a ceiling effect and is typically a screening tool rather than a continuous measure of sociability.
  • Evident from the text: only male mice were studied, drug treatment was acute, and no chronic dosing, safety, or human data are reported.
  • Evident from the text: the fmr1−/− baseline social deficit was not statistically significant in this study, and the proposed oxytocin–anandamide reward mechanism was not directly tested in these ASD models.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1089/can.2015.0008

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 44 cited sources checked · 0 supported · 0 flagged

Show all 25 claims

  • It may state two separate claims as one. 11
  • Probably not a substantial claim. 25
33 of 33
  • The paper relies on this without support.

    The underlying basis for social impairment in ASD is unknown, and no pharmacological treatment is available.

    “The underlying basis for social impairment in ASD is unknown, and no pharmacological treatment is available.”
  • The paper relies on this without support.

    Social reward is a key aspect of social functioning that is disrupted in ASD.

    “social reward is a key aspect of social functioning that is thought to be disrupted in ASD.”
2 of 2

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 51 references

1 of the 51 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Jung K-M, 2012, Nat Commun, 3, 108
  2. Kerr DM, 2013, Behav Brain Res, 30, 680

Cited by

Sorted by citations

Items 101–122 of 122

Metadata

Authors
Wei, D., Dinh, D., Lee, D., Li, D., Anguren, A., Moreno-Sanz, G., Gall, C. M., & Piomelli, D.
Affiliations
  • Department of Anatomy and Neurobiology, University of California, Irvine, Irvine, California.
  • University of California, Irvine (US)
  • Harbin Medical University (CN)
Corresponding author
Piomelli, Daniele
Venue
Cannabis and Cannabinoid Research
Published
2016-12
Volume
1
Issue
1
Pages
81-89
ISSN
2378-8763 (ISSN-L)
OpenAlex
W2293191501
Cited by
122
References
51
Citations by year
2026: 4 · 2025: 17 · 2024: 15 · 2023: 14 · 2022: 11 · 2021: 25 · 2020: 11 · 2019: 14 · 2018: 3 · 2017: 4 · 2016: 4
FWCI
6.75
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cannabis and Cannabinoid Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Autism Science Foundation
  • National Institutes of Health
  • University of California, Irvine
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
Keywords
anandamide, endocannabinoid system, autism spectrum disorder, social dysfunction, oxytocin, social reward, fatty acid amide hydrolase, FAAH inhibition, URB597, CB1 receptor, BTBR mice, Fmr1 knockout mice, fragile X syndrome, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review